keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/28737972/identifying-health-information-technology-needs-of-oncologists-to-facilitate-the-adoption-of-genomic-medicine-recommendations-from-the-2016-american-society-of-clinical-oncology-omics-and-precision-oncology-workshop
#1
Kevin S Hughes, Edward P Ambinder, Gregory P Hess, Peter Paul Yu, Elmer V Bernstam, Mark J Routbort, Jean Rene Clemenceau, John T Hamm, Phillip G Febbo, Susan M Domchek, James L Chen, Jeremy L Warner
At the ASCO Data Standards and Interoperability Summit held in May 2016, it was unanimously decided that four areas of current oncology clinical practice have serious, unmet health information technology needs. The following areas of need were identified: 1) omics and precision oncology, 2) advancing interoperability, 3) patient engagement, and 4) value-based oncology. To begin to address these issues, ASCO convened two complementary workshops: the Omics and Precision Oncology Workshop in October 2016 and the Advancing Interoperability Workshop in December 2016...
July 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28737963/2017-asco-quality-care-symposium-nurturing-a-new-and-growing-community-of-practitioners
#2
Michael Neuss, Joseph Jacobson, Monika Krzyzanowska
No abstract text is available yet for this article.
July 24, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28734596/developments-in-urologic-oncology-%C3%A2-oncoforum%C3%A2-the-best-of-2016
#3
F Gómez-Veiga, A Alcaraz-Asensio, J Burgos-Revilla, J M Cózar-Olmo
OBJECTIVE: To put forth new findings of urologic oncology with impact on clinical practice presented during 2016 in the main annual meetings. ACQUISITION OF EVIDENCE: This document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee. SYNTHESIS OF EVIDENCE: In High-Risk Renal-Cell carcinoma after nephrectomy, disease-free survival was significantly greater for sunitinib than placebo group, with adverse events more frequents...
July 19, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28725278/asco-2016-update-colorectal-liver-metastases
#4
REVIEW
Klaus Kaczirek
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM...
2017: Memo
https://www.readbyqxmd.com/read/28717759/quality-oncology-practice-initiative-can-guide-and-improve-oncology-providers-training-in-brazil
#5
Cristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, Simone Elias, Daiane Pereira Guimarães, Nora Manoukian Forones, Otavio Cesar Carvalho Guimarães Baiocchi, Nildo Alves Batista, Edvane Birelo Lopes De Domenico
PURPOSE: It has become crucial to translate scientific findings and to find ways by which to mobilize local resources to improve the quality and accessibility of cancer care in developing countries. This study seeks to provide insight into challenge through examining differences in clinician documentation of patients with cancer treated at a Brazilian Public University Hospital. METHODS: ASCO Quality Oncology Practice Initiative (QOPI) measures were used to examine the care provided in the departments of breast, colorectal, lymphoma, gynecology, and lung cancers...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717717/management-and-care-of-women-with-invasive-cervical-cancer-american-society-of-clinical-oncology-resource-stratified-clinical-practice-guideline
#6
Linus T Chuang, Sarah Temin, Rolando Camacho, Alfonso Dueñas-Gonzalez, Sarah Feldman, Murat Gultekin, Vandana Gupta, Susan Horton, Graciela Jacob, Elizabeth A Kidd, Kennedy Lishimpi, Carolyn Nakisige, Joo-Hyun Nam, Hextan Yuen Sheung Ngan, William Small, Gillian Thomas, Jonathan S Berek
PURPOSE: To provide evidence-based, resource-stratified global recommendations to clinicians and policymakers on the management and palliative care of women diagnosed with invasive cervical cancer. METHODS: ASCO convened a multidisciplinary, multinational panel of cancer control, medical and radiation oncology, health economic, obstetric and gynecologic, and palliative care experts to produce recommendations reflecting resource-tiered settings. A systematic review of literature from 1966 to 2015 failed to yield sufficiently strong quality evidence to support basic- and limited-resource setting recommendations; a formal consensus-based process was used to develop recommendations...
October 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28714765/comparison-of-estrogen-and-progesterone-receptor-antibody-reagents-using-proficiency-testing-data
#7
Megan L Troxell, Thomas Long, Jason L Hornick, Abiy B Ambaye, Kristin C Jensen
CONTEXT: - Immunohistochemical analysis of estrogen receptor (ER) and progesterone receptor (PgR) expression in breast cancer is the current standard of care and directly determines therapy. In 2010 the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) published guidelines for ER and PgR predictive testing, encompassing preanalytic, analytic, postanalytic factors; antibody validation; and proficiency testing. OBJECTIVE: - To compare the performance of different antibody reagents for ER and PgR immunohistochemical analysis by using CAP proficiency testing data...
July 17, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28712790/prognostic-factors-for-tumor-recurrence-in-patients-with-clinical-stage-i-seminoma-undergoing-surveillance-a-systematic-review
#8
REVIEW
Friedemann Zengerling, Frank Kunath, Katrin Jensen, Christian Ruf, Stefanie Schmidt, Annabel Spek
OBJECTIVE: To systematically evaluate evidence on prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance. METHODS: Systematic literature search conducted of Medline, Web of Science, Cochrane Library, and the conference proceedings of the ASCO, AUA, and EAU meetings (last search: October 2016), according to our prospectively registered protocol (PROSPERO registration number CRD42014009434). Identified records were reviewed according to the Cochrane Method Group of Prognosis Reviews recommendations and the PRISMA reporting guideline...
July 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28712615/predicting-real-world-effectiveness-of-cancer-therapies-using-overall-survival-and-progression-free-survival-from-clinical-trials-empirical-evidence-for-the-asco-value-framework
#9
Darius N Lakdawalla, Jason Shafrin, Ningqi Hou, Desi Peneva, Seanna Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer, Robert A Figlin
OBJECTIVES: To measure the relationship between randomized controlled trial (RCT) efficacy and real-world effectiveness for oncology treatments as well as how this relationship varies depending on an RCT's use of surrogate versus overall survival (OS) endpoints. METHODS: We abstracted treatment efficacy measures from 21 phase III RCTs reporting OS and either progression-free survival or time to progression endpoints in breast, colorectal, lung, ovarian, and pancreatic cancers...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712009/analysis-of-molecular-subtypes-for-the-increased-her2-equivocal-cases-caused-by-application-of-the-updated-2013-asco-cap-her2-testing-guidelines-in-breast-cancer
#10
Lei Guo, Pei Yuan, Jing Zhang, Yun Ling, Wenbin Li, Bohui Zhao, Jianming Ying, Lixue Xuan
PURPOSE: Accurate testing of the status of human epidermal growth factor receptor type 2 (HER2) is a prerequisite for HER2-directed therapy. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) published joint guideline recommendations for HER2 testing in breast cancer in 2007 and it was updated in 2013. We compared the HER2 gene amplification status based on these two guidelines and analyzed the molecular characteristics of the equivocal cases...
July 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28702778/characterization-of-her2-gene-amplification-heterogeneity-in-invasive-and-in-situ-breast-cancer-using-bright-field-in-situ-hybridization
#11
António Polónia, Guilherme Oliveira, Fernando Schmitt
The aims of this study were to evaluate and compare the HER2 gene amplification status in invasive and adjacent in situ breast carcinoma, using bright-field in situ hybridization, and to document the possible presence of HER2 genetic heterogeneity (HER2-GH) in both components. A cohort of 100 primary invasive carcinomas (IC) associated with carcinoma in situ (CIS) were evaluated for HER2 gene amplification by SISH according to the 2013 ASCO/CAP HER2 guideline. A second cohort of all the cases with HER2-GH since the introduction of the updated ASCO/CAP HER2 guideline was also characterized, and an evaluation of the HER2 gene amplification in the CIS component, if present, was also done...
July 13, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28702501/patterns-of-cervical-cancer-care-in-argentina-applying-asco-recommendations-adjusted-by-local-resources
#12
REVIEW
Agustín Apás Pérez De Nucci, Lucas Minig, Myriam Perrotta
There are significant differences in cervical cancer incidence and mortality between low-middle and high-income countries. The American Society of Clinical Oncology (ASCO) resource-stratified clinical practice guideline was designed to provide an appropriate cervical cancer treatment based on the best available evidence in scenarios with different diagnostic and therapeutic resources. Argentina, a Latin American high middle income country, shows however, that cervical cancer rates are similar to those of low-income countries...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28702401/outcome-of-her2-testing-by-fish-applying-asco-cap-2007-and-2013-guideline-in-ihc-equivocal-group-of-breast-cancer-experience-at-tertiary-cancer-care-centre
#13
Manoj Kumar Panigrahi, Dushyant Kumar, Anurag Mehta, Kandarpa Kumar Saikia
BACKGROUND AND OBJECTIVES: HER2 testing guideline of ASCO/CAP for interpretation and reporting has recently been revised. The study is aimed to measure the impact of 2013 CAP guideline on equivocal HER2 test outcome (immunohistochemistry [IHC] 2+) when tested by fluorescent in situ hybridization (FISH). The study also aims at finding the frequency of polysomy and monosomy of chromosome 17. MATERIALS AND METHODS: Specimens were collected in Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28698389/the-best-thing-i-saw-at-asco
#14
Mark A Lewis
No abstract text is available yet for this article.
July 11, 2017: Oncologist
https://www.readbyqxmd.com/read/28695299/adjuvant-ovarian-suppression-for-resected-breast-cancer-2017-critical-assessment
#15
EDITORIAL
Steven E Vogl
Currently available data supporting adjuvant ovarian function suppression for resected breast cancer in premenopausal women in addition to standard chemotherapy and tamoxifen are not persuasive, even though an ASCO guideline supports them. Available information from the key trial, called "SOFT," has only 5-year follow-up in a 15-year disease. It employs breast cancer events as an endpoint, rather than distant metastases, or better still, death from any cause. The small advantages reported to date may disappear when aromatase inhibitors are given after the occurrence of menopause in the control population...
July 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28693218/meta-analysis-of-the-role-of-bevacizumab-in-extensive-stage-small-cell-lung-cancer
#16
Yan-Juan Zhu, Hai-Bo Zhang, Yi-Hong Liu, Jian-Ping Bai, Yong Li, Li-Rong Liu, Yan-Chun Qu, Xin Qu, Xian Chen
Progress in the treatment options for small cell lung cancer (SCLC) remains poor. Concerns exist regarding the efficacy of bevacizumab in SCLC. The present study aimed to evaluate the efficacy of bevacizumab in extensive stage (ES)-SCLC. A meta-analysis on studies conducted and listed on the Medline, Cochrane Trials, ASCO, ESMO and ClinicalTrial databases, and Chinese databases prior to April 2015 was performed. All clinical trials in which patients with ES-SCLC were treated with bevacizumab were considered...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28692382/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-early-stage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-focused-update
#17
Ian Krop, Nofisat Ismaila, Fabrice Andre, Robert C Bast, William Barlow, Deborah E Collyar, M Elizabeth Hammond, Nicole M Kuderer, Minetta C Liu, Robert G Mennel, Catherine Van Poznak, Antonio C Wolff, Vered Stearns
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate guideline updates. For this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study to evaluate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal. An expert panel reviewed the results of the MINDACT study along with other published literature on the MammaPrint assay to assess for evidence of clinical utility...
July 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28689236/etiological-classification-of-ischemic-stroke-in-young-patients-a-comparative-study-of-toast-ccs-and-asco
#18
Elif Gökçal, Elvin Niftaliyev, Talip Asil
Analysis of stroke subtypes is important for making treatment decisions and prognostic evaluations. The TOAST classification system is most commonly used, but the CCS and ASCO classification systems might be more useful to identify stroke etiologies in young patients whose strokes have a wide range of different causes. In this manuscript, we aim to compare the differences in subtype classification between TOAST, CCS, and ASCO in young stroke patients. The TOAST, CCS, and ASCO classification schemes were applied to 151 patients with ischemic stroke aged 18-49 years old and the proportion of subtypes classified by each scheme was compared...
July 8, 2017: Acta Neurologica Belgica
https://www.readbyqxmd.com/read/28688674/a-network-meta-analysis-of-the-sequencing-and-types-of-systemic-therapies-with-definitive-radiotherapy-in-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-lascchn-%C3%A2
#19
Katarzyna J Jerzak, Keemo Delos Santos, Ronak Saluja, Kelly Lien, Justin Lee, Kelvin K W Chan
OBJECTIVES: The current standard therapy for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is platinum-based chemotherapy plus concurrent radiotherapy (CRT), but several systemic therapies have been evaluated. We performed a Bayesian network meta-analysis (NMA) with random effects to enable direct and indirect comparisons of all existing treatment modalities for LASCCHN simultaneously. MATERIAL AND METHODS: A systematic review was conducted using MEDLINE, EMBASE, ASCO abstracts, ASTRO abstracts and the Cochrane Central of Registered Trials using Cochrane methodology to identify randomized controlled trials (RCTs) up to June 2016...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28657360/a-current-and-comprehensive-review-of-cyclin-dependent-kinase-%C3%A4-nhibitors-for-the-treatment-of-metastatic-breast-cancer
#20
Burak Bilgin, Mehmet An Sendur, Didem Şener Dede, Muhammed Bülent Akıncı, Bülent Yalçın
BACKGROUND: Resistance to endocrine treatment generally occurs over time, especially in the metastatic stage. In this paper, we aimed to review the mechanisms of cyclin-dependent kinases (CDK) 4/6 inhibition and clinical usage of new agents in the light of recent literature updates. SCOPE: A literature search was carried out using PubMed, Medline and ASCO and ESMO annual-meeting abstracts by using the following search keywords; "palbociclib", "abemaciclib", "ribociclib", "cyclin-dependent kinase inhibitors" and "CDK 4/6" in metastatic breast cancer (MBC)...
June 28, 2017: Current Medical Research and Opinion
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"